ライフサイエンスコーパス: amiodarone

1 patients off medication (except 1 patient on amiodarone).

2 33 to 0.99] for ICD; 0.44 [0.24 to 0.80] for amiodarone).

3 s), as well as drug-induced steatosis (i.e., amiodarone).

4 r high-risk medications (eg, spironolactone, amiodarone).

5 on and recent studies have shown promise for amiodarone.

6 entifying patients eligible for prophylactic amiodarone.

7 aining 36 (66%) did so spontaneously or with amiodarone.

8 nge 8 weeks after the patient stopped taking amiodarone.

9 uvir and daclatasvir by 2 patients receiving amiodarone.

10 odarone-treated patients and patients not on amiodarone.

11 reated patients and patients who were not on amiodarone.

12 were compared with those who did not receive amiodarone.

13 One patient in each group was on amiodarone.

14 ay, and non-CV death were more frequent with amiodarone.

15 he efficacy and safety of dronedarone versus amiodarone.

16 miodarone, and 1 trial of dronedarone versus amiodarone.

17 l and patient specific factors on the use of amiodarone.

18 drug; 8,883 (60%) of these patients received amiodarone.

19 c drug; 108 (40%) of these patients received amiodarone.

20 d VT recurrence and ICD shocks compared with amiodarone.

21 odrugs elicit bradycardia when combined with amiodarone.

22 terol is correlated with the accumulation of amiodarone.

23 e in the recipient pretransplantation use of amiodarone.

24 I antiarrhythmic drugs, and 62 (22%) were on amiodarone.

25 inhibitors may exhibit this cardiac DDI with amiodarone.

26 J774A-1 macrophages were exposed to amiodarone (10 muM) or medium for 24 h and chemically fi

27 In all, 16 (4.1%) amiodarone, 11 (3.1%) lidocaine, and 6 (1.9%) placebo-tr

28 ion consisted mostly of beta-blockers (38%), amiodarone (14%), or sotalol (30%).

29 Amiodarone (200 mg/d after loading dose of 600 mg/d for

30 6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%).

31 is against POAF with beta-blockers (85%) and amiodarone (28%) was allowed on the basis of caregivers'

32 .6% (1.1% to 4.1%) in patients randomized to amiodarone, 3.2% (1.8% to 4.7%) in patients randomized t

33 amiodarone infusion, or a 60-min infusion of amiodarone (5 mg/kg) followed by a maintenance infusion

34 irst CVH event rates at 3 years were 47% for amiodarone, 50% for sotalol, and 44% for Class 1C versus

35 higher rate of symptom relief compared with amiodarone (53.4% of vernakalant patients reported no AF

36 ic range that was lower than patients not on amiodarone (56.5% vs. 63.0%; p < 0.0001).

37 ion, 3026 patients were randomly assigned to amiodarone (974), lidocaine (993), or placebo (1059); of

38 cellular uptake of the antiarrhythmic agent amiodarone, a phospholipidosis-inducing pharmaceutical c

39 Amiodarone accumulates in the liver, where it increases

40 of liver damage earlier as well as to verify amiodarone accumulation in the liver.

41 icular tachycardia/ventricular fibrillation, amiodarone (adjusted hazard ratio 0.39, 95% confidence i

42 (adjusted odds ratio, 1.5; 95% CI, 1.1-2.1), amiodarone (adjusted odds ratio, 3.4; 95% CI, 2.9-4.0),

43 8.8]); but not in recipients of intraosseous amiodarone (adjusted risk ratio, 0.94 [95% CI, 0.66-1.32

44 ficantly higher in recipients of intravenous amiodarone (adjusted risk ratio, 1.26 [95% CI, 1.06-1.50

45 ted a further reduction in heart rate during amiodarone administration, indicating that the reduction

46 iently expressing human SK2 before and after amiodarone administration.

47 Amiodarone also caused rapid nuclear accumulation of the

48 e cytotoxic effects observed in cancer cells Amiodarone also has an indirect effect on angiogensis, a

49 idocaine, while 67% of children who received amiodarone also received lidocaine (p < .001).

50 e percent of adults with VF/pVT who received amiodarone also received lidocaine, while 67% of childre

51 Desethylamiodarone, a major metabolite of amiodarone, also exerts voltage-independent but Ca(2+) d

52 tion between nitrophenols (pi-acceptors) and amiodarone (AM) was performed using electronic absorptio

53 It is known that amiodarone (AMD) acts on hERG K(+) channels to treat car

54 Amiodarone (AMD) and nifekalant (NIF) are used in the tr

55 Amiodarone (AMD), a widely prescribed class III antiarrh

56 eve absolute cell quantification of the drug amiodarone (AMIO) and its major metabolite, N-desethylam

57 hether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial

58 tivirals (DAAs) and the antiarrhythmic drug, amiodarone (AMIO).

59 The amiodarone analog N-ethylamiodarone (NEA) did not alter

60 Both amiodarone and desethylamiodarone inhibit I KAS at thera

61 azine may be of benefit as an alternative to amiodarone and dofetilide in the management of AF in pat

62 The long-term side effects of amiodarone and early complications of CA should be weigh

63 ase (CVD), pregnancy, and in patients taking amiodarone and isotretinoin.

64 e further confirmed by the autophagy inducer amiodarone and miR-224 antagonist using an orthotopic SD

65 biomicroscopy), and serum concentrations of amiodarone and N-desethylamiodarone also were determined

66 Two healthy controls (one treated with amiodarone and one unmedicated) underwent electroanatomi

67 Amiodarone and propranolol were stopped, but the patient

68 The second patient was taking amiodarone and propranolol; 2 hrs after receiving sofosb

69 tantly, through a direct demonstration using amiodarone and rifampicin as model drugs, we showed that

70 s was used to assess the association between amiodarone and the occurrence of optic neuropathy.

71 th main effects for randomized treatment and amiodarone and their interaction.

72 with those who qualified but did not receive amiodarone and those not evaluated (11.1% versus 38.7% a

73 dronedarone, 4 placebo-controlled trials of amiodarone, and 1 trial of dronedarone versus amiodarone

74 ed with different concentrations of the drug amiodarone, and we observed that the upregulation of pho

75 adults who had received standard CPR in the amiodarone arm of the ALPS trial (Amiodarone, Lidocaine,

76 s (11 for atrial arrhythmias), and 2 were on amiodarone as a bridge to heart transplantation.

77 dings lay the ground for further research of Amiodarone as a possible clinical agent that, used in sa

78 Amiodarone-associated thyrotoxicosis and Graves' disease

79 r docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole,

80 Hek 293 have a significantly lower amount of amiodarone at 0.43 and 0.36 pg per cell, respectively.

81 ine characteristics of patients who received amiodarone at randomization were compared with those who

82 n ARISTOTLE, 2,051 (11.4%) patients received amiodarone at randomization.

83 atients who received and who did not receive amiodarone at the time of randomization.

84 Use of amiodarone before transplant was associated with a nonsi

85 rence of LAE before and after treatment with amiodarone, beta-blockers, sotalol, or ablation.

86 Patients newly treated with amiodarone between 2005 and 2009 were identified from th

87 rrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effe

88 of nutrient-responsive genes was affected by amiodarone but not CaCl(2), indicating that activation o

89 ntiarrhythmic therapy, including intravenous amiodarone, but invariably responded to quinidine therap

90 lar accumulation of L-ala,SP metabolites +/- amiodarone, but no D-ala,RP metabolites were detected.

91 /ventricular fibrillation who survive 3 hrs, amiodarone, but not lidocaine, is associated with an inc

92 transcriptional response of S. cerevisiae to amiodarone by DNA microarray.

93 ference in all-cause hospitalization between amiodarone, Class Ic, and sotalol.

94 The corresponding HRs for amiodarone compared to placebo were 0.68 (95% CI: 0.46 t

95 Over a median 45.5-month follow-up, amiodarone, compared with placebo, did not affect surviv

96 In conclusion, amiodarone competes with NEA at a novel, extracellular,

97 Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm.

98 of accurately subtracting iodine of hepatic amiodarone-deposits.

99 Pretreatment with amiodarone did not increase the success rates.

100 alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% CI, 9.76-18.13]); 102

101 5 in an independent replication cohort of 28 amiodarone dLQTS cases versus 173 control subjects (meta

102 Similar to amiodarone, dronedarone is a potent blocker of multiple

103 bolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these ef

104 Amiodarone enhanced the maximal level of agonist-stimula

105 of optic neuropathy in patients treated with amiodarone, especially in males and possibly in patients

106 antiarrhythmic drugs (including intravenous amiodarone) fail.

107 vular atrial fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compare

108 Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NO

109 atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, vor

110 ernakalant demonstrated efficacy superior to amiodarone for acute conversion of recent-onset AF.

111 atients received digoxin, beta-blockers, and amiodarone for rate control; device interrogation showed

112 cy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atri

113 Dronedarone is less effective than amiodarone for the maintenance of sinus rhythm, but has

114 quantitative measurements of cell-associated amiodarone for the population using LC/MS/MS and cell co

115 n which the authors evaluated dronedarone or amiodarone for the prevention of AF.

116 he efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibril

117 synthesize evidence regarding optimal use of amiodarone for various arrhythmias.

118 tal diameter was significantly higher in the amiodarone group compared with the control group (AK gro

119 However, only 14 patients (25%) in the amiodarone group received the recommended initial 300-mg

120 00-mg groups, respectively; and 45.3% in the amiodarone group.

121 pixaban with warfarin, patients who received amiodarone had a stroke or a systemic embolism rate of 1

122 Amiodarone had no effect on all-cause mortality or its c

123 Compared with placebo, amiodarone had no significant effect on any mode of deat

124 The use of amiodarone had no significant effects on the primary qua

125 Amiodarone had the lowest risk of AF hospitalization and

126 Patients on warfarin and amiodarone had time in the therapeutic range that was lo

127 However, amiodarone has a number of serious adverse effects, incl

128 The antiarrhythmic drug amiodarone has fungicidal activity against a broad range

129 rom a small number of patients suggests that amiodarone has superior efficacy in preventing ventricul

130 owed better outcomes with Rate compared with amiodarone (hazard ratio [HR]: 1.18, 95% confidence inte

131 s 40%, 40%, and 36%, respectively, for Rate (amiodarone HR: 1.20, 95% CI: 1.03 to 1.40, p = 0.02, sot

132 R] 1.59; 95% confidence interval 1.13-2.24), amiodarone (HR 2.63; 1.77-3.89), and sotalol (HR 1.72; 1

133 a nonsignificant increase in mortality with amiodarone (HR: 1.20, 95% CI: 0.94 to 1.53, p = 0.15) wi

134 ive care unit stay or death was shorter with amiodarone (HR: 1.22, 95% CI: 1.02 to 1.46, p = 0.03).

135 4; p = 0.001) and with the administration of amiodarone (HR: 268; p < 0.001).

136 Compared with control, amiodarone (HR=0.33 [95% CrI=0.15-0.76]; absolute risk d

137 ncreased risk of VT recurrence compared with amiodarone (HR=2.88 [95% CrI=1.35-6.46]).

138 ent arms (ICD, HR 1.54, 95% CI 1.04 to 2.27; amiodarone, HR 1.33, 95% CI 0.91 to 1.93; and placebo, H

139 ate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs)

140 mean of 2.4 antiarrhythmic drugs, including amiodarone in 29 (47%) patients.

141 upon accidental intra-arterial injection of amiodarone in an emergency setting.

142 ive magnesium and steroids, and preoperative amiodarone in high-risk patients should be rigorously ev

143 hod that has been shown to enable imaging of amiodarone in single rat macrophage (NR8383) cells.

144 hase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrilla

145 ion of landmark studies and the inclusion of amiodarone in the American Heart Association Guidelines

146 usion or exclusion of patients randomized to amiodarone in the analyses.

147 clinical events and bleeding with the use of amiodarone in the ARISTOTLE (Apixaban for Reduction in S

148 oup difference, with earlier prescription of amiodarone in the placebo group (P=0.022).

149 median of 2 antiarrhythmic drugs), including amiodarone, in 166 (59%) patients.

150 Amiodarone increased atrial APD and reduced APD heteroge

151 approach to the management of patients with amiodarone-induced alterations in thyroid function tests

152 allows differentiation of type 1 from type 2 amiodarone-induced hyperthyroidism.

153 ogies include destructive thyroiditis (e.g., amiodarone-induced thyroid dysfunction) and factitious h

154 Pre-clinical studies suggest that Amiodarone induces cytotoxicity in several types of canc

155 fusion (2 mg/kg) if still in AF, plus a sham amiodarone infusion, or a 60-min infusion of amiodarone

156 pendent, but was Ca(2+)-dependent: 30 microM amiodarone inhibited 81.5+/-1.9% of I KAS induced with 1

157 Amiodarone inhibited IKAS in a dose-dependent manner (IC

158 We have reported previously that amiodarone interacts with muscarinic receptors via a nov

159 Amiodarone is an anti-arrhythmic drug that was approved

160 Amiodarone is an effective medication in preventing atri

161 Although amiodarone is approved by the US Food and Drug Administr

162 Amiodarone is effective in maintaining sinus rhythm in a

163 The only role for prophylactic amiodarone is in the perioperative period of cardiac sur

164 Amiodarone is proarrhythmic and should be avoided in pat

165 Amiodarone is the most effective antiarrhythmic drug for

166 Amiodarone is the most frequently used agent for maintai

167 Amiodarone is useful in acute management of sustained ve

168 mpflug corneal densitometry in patients with amiodarone keratopathy (AK).

169 Co-applied with amiodarone, L-ala,SP prodrugs increased beating rate and

170 LPS trial (Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study), when stratified

171 , double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with st

172 patients receiving epinephrine, vasopressin, amiodarone, lidocaine, atropine, bicarbonate, calcium, m

173 ctively randomized, double-blind, to receive amiodarone, lidocaine, or placebo by paramedics.

174 he analysis was replicated among ALPS trial (Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Car

175 a from the Resuscitation Outcomes Consortium Amiodarone, Lidocaine, or Placebo Study trial.

176 CPR in the amiodarone arm of the ALPS trial (Amiodarone, Lidocaine, or Placebo Study).

177 Low dose Amiodarone markedly reduced the size of GBM xenograft tu

178 The clinical efficacy and toxicity of amiodarone may be determined more effectively by tissue

179 Amiodarone may be effective as an adjunct to implantable

180 Amiodarone may have clinical value in patients with left

181 ditions and nitrogen depletion suggests that amiodarone may interfere with nutrient sensing and regul

182 We revealed Amiodarone-mediated QTc prolongation, HR reduction and H

183 btained when the macrophages were doped with amiodarone metabolite, desethylamiodarone.

184 Those on amiodarone (n = 10) had a significantly lower risk of an

185 atients received lidocaine (n = 664, 59.0%), amiodarone (n = 50, 4.4%), both (n = 110, 9.8%), or no a

186 ted with antiarrhythmic drugs (most commonly amiodarone [n=103] or sotalol [n=78]) and AF catheter ab

187 for inclusion (n=79 for lidocaine, n=74 for amiodarone, n=41 for combination).

188 Overall, neither amiodarone nor lidocaine resulted in a significantly hig

189 t the reduction was the result of actions of amiodarone on I(Na), I(Kur), I(CaL), I(CaT), I(f) and be

190 mes were published before the routine use of amiodarone or ablation therapies.

191 t PVCs and DCM were substantially reduced by amiodarone or flecainide, which are drugs that have sodi

192 redictors of thromboembolism; treatment with amiodarone or ICD treatment was a significant predictor

193 Those treated with amiodarone or ICDs had lower risk of thromboembolism tha

194 odification by drug administration route for amiodarone or lidocaine in comparison with placebo durin

195 nt estimates for survival were greater after amiodarone or lidocaine than placebo, without increased

196 randomly assigned 2521 patients to placebo, amiodarone, or ICD between 1997 and 2001.

197 D-HeFT regardless of treatment arm (placebo, amiodarone, or ICD).

198 CD-HeFT randomized 2521 subjects to placebo, amiodarone, or shock-only, single-lead ICD therapy.

199 nction, or concomitant use of beta-blockers, amiodarone, or warfarin.

200 g increasing INR (antiarrhythmics class III [amiodarone], other opioids [tramadol], glucocorticoids,

201 alant patients compared with 6 of 116 (5.2%) amiodarone patients (p < 0.0001).

202 liver-attenuation and LAI were not higher in amiodarone patients in VNC-Chest and in VNC-Abdomen.

203 Seven hundred twenty-nine amiodarone patients, 606 sotalol patients, and 268 Class

204 AF symptoms at 90 min compared with 32.8% of amiodarone patients; p = 0.0012).

205 patients with moderate heart failure (HF) to amiodarone, placebo drug, or implantable cardioverter-de

206 Settings in which amiodarone prophylaxis against atrial fibrillation after

207 patients, of which 21 have been treated with amiodarone, receiving SDCT-examinations (unenhanced-ches

208 More amiodarone recipients required temporary cardiac pacing

209 Among antiarrhythmic drugs, only amiodarone reduces VAs, although its use may be associat

210 Overall, the transcriptional responses to amiodarone revealed by this study were found to be disti

211 SK2 current inhibition may in part underlie amiodarone's effects in preventing electrical storm in f

212 In this study, we examined Amiodarone's effects on a murine tumor model comprised o

213 that reserve by receptor alkylation unmasked amiodarone's enhancement of the maximal IP response to a

214 Amiodarone, sedation, sodium channel-blocking agents, an

215 rvations indicate that patients treated with amiodarone should be continuously monitored within the f

216 Amiodarone should be used with close follow-up in patien

217 effectiveness (in the rate-control group) or amiodarone side effects or adverse drug reactions (in th

218 Among patients with an ICD, amiodarone significantly reduced VT recurrence and ICD s

219 Amiodarone, sofosbuvir, and daclatasvir treatment were s

220 Compared with amiodarone, sotalol was associated with significantly in

221 e who received their first AAD prescription (amiodarone, sotalol, dronedarone, or Class Ic) within 14

222 Drug treatment with beta-blockers, amiodarone, statins, steroids, magnesium, and sotalol ca

223 model incorporating all trial evidence found amiodarone superior to dronedarone (OR: 0.49; 95% CI: 0.

224 A moderate dose of amiodarone temporarily delayed cell cycle progression at

225 ardiovascular hospitalization was lower with amiodarone than Class Ic (HR 0.80; 0.70-0.92), but not n

226 y have different benefits from lidocaine and amiodarone than previously demonstrated.

227 e is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment of

228 In patients who did not receive amiodarone, the stroke or systemic embolism rate was 1.2

229 nsive care units (< or = 50 beds) to receive amiodarone; the association persisted in multivariable a

230 Sixty-six patients receiving amiodarone therapy and 66 healthy controls were consecut

231 roup of SCD-HeFT patients who were harmed by amiodarone therapy and did not benefit from ICD.

232 st patients have complete VT control without amiodarone therapy and limited need for antiarrhythmic d

233 or quantifying AK and can help in monitoring amiodarone therapy.

234 achycardia of 190 beats/min was administered amiodarone through an accidently placed arterial access

235 nd device-based interventions such as adding amiodarone to baseline beta-blocker therapy, adjusting I

236 the perinuclear region (i.e., cytoplasm) of amiodarone-treated cells had significantly elevated band

237 ear and perinuclear regions of untreated and amiodarone-treated cells showed that the perinuclear reg

238 AFM topography maps revealed amiodarone-treated cells with enlarged cytoplasm and ver

239 nal period, optic neuropathy developed in 17 amiodarone-treated patients (0.3%) and 30 control patien

240 The analysis included 6175 amiodarone-treated patients and 24 700 controls.

241 ted, but were not significantly different in amiodarone-treated patients and patients not on amiodaro

242 and major bleeding compared with warfarin in amiodarone-treated patients and patients who were not on

243 ivariate Cox regression analysis showed that amiodarone-treated patients had a 2-fold increased risk

244 More amiodarone-treated patients had a stroke or a systemic e

245 Among amiodarone-treated patients, male gender was associated

246 matched control subjects who did not receive amiodarone treatment.

247 cipient African American race, and recipient amiodarone treatment.

248 Amiodarone use (24 patients [26%]) and antithyroid-drug

249 Amiodarone use and hospitalization decreased from 55% an

250 teady 3-year nonrecurrence rate with reduced amiodarone use and hospitalizations indicate improved lo

251 The interaction p values for amiodarone use by apixaban treatment effects were not si

252 To examine practice patterns of amiodarone use during in-hospital cardiac arrest.

253 There has been a significant increase in amiodarone use for VF/pVT events over the past 5 yrs.

254 In adults, amiodarone use for VF/pVT increased from 25% in 2000 to

255 The frequency of amiodarone use in adults correlated positively with the

256 This study addresses the changing pattern of amiodarone use over time, following the publication of l

257 After stratification by gender, amiodarone use remained a significant factor for optic n

258 Amiodarone use was associated with significantly increas

259 rea [BSA], chronic kidney disease [CKD], and amiodarone use) and genetic factors (CYP2C9*2, *3, *5, *

260 rfarin dose was influenced by age, BSA, CKD, amiodarone use, and CYP2C9*3 and VKORC1 variants in both

261 , serum creatinine concentration, digoxin or amiodarone use, and QRS duration near 130-ms peak.

262 -year) survival, symptomatic VT control, and amiodarone use.

263 ions were more pronounced in the subgroup of amiodarone users, in which 3 SNPs, including rs10800397,

264 ion in patients treated and not treated with amiodarone using true-non-contrast (TNC) and virtual-non

265 sotalol (HR 1.72; 1.17-2.54), but lower with amiodarone versus Class Ic (HR 0.68; 0.57-0.80) and sota

266 e events requiring drug discontinuation with amiodarone versus dronedarone (OR: 1.81; 95% CI: 1.33 to

267 The effect of amiodarone versus dronedarone was summarized by the use

268 oints (95% CI, -1.0 to 6.3; P=0.16); and for amiodarone versus lidocaine, 0.7 percentage points (95%

269 ant estimated reduction in recurrent AF with amiodarone versus placebo (odds ratio [OR]: 0.12; 95% co

270 The difference in survival rate for amiodarone versus placebo was 3.2 percentage points (95%

271 nshockable-turned-shockable arrhythmias with amiodarone versus placebo were 2.3% (-0.3, 4.8), P=0.08,

272 non-CV death being significantly higher with amiodarone versus Rate (HR: 1.11, 95% CI: 1.01 to 1.24,

273 mended initial 300-mg intravenous bolus, and amiodarone was administered an average of 8 mins later i

274 ncy warned that bradycardia could occur when amiodarone was administered in combination with sofosbuv

275 The use of amiodarone was associated with a significantly reduced r

276 Among patients who survived 3 hrs, amiodarone was associated with increased mortality at 30

277 From this spatial analysis, amiodarone was detected throughout the cell, with the ma

278 The dose of amiodarone was increased if it had been less than 300 mg

279 In the escalated-therapy group, amiodarone was initiated if another agent had been used

280 IKAS inhibition by amiodarone was not voltage-dependent, but was Ca(2+)-dep

281 A similar effect of amiodarone was observed when pilocarpine was used to sti

282 tion of the HCV-NS5B prodrug sofosbuvir with amiodarone was recently reported.

283 Amiodarone was searched using the terms adverse effects,

284 interaction between randomized treatment and amiodarone was tested using a Cox model, with main effec

285 ajority of JET patients (89%), and of those, amiodarone was the most commonly reported effective agen

286 Amiodarone was the most frequently used medication alone

287 Amiodarone was the primary treatment in 63% of cases, 1%

288 Intravenous amiodarone was used in 46%, electric cardioversion in 28

289 time to prescription of recovery medication (amiodarone) was the only parameter showing an intergroup

290 patients treated with dronedarone instead of amiodarone, we estimate approximately 228 more recurrenc

291 erived from TNC-images of patients receiving amiodarone were higher.

292 s III anti-arrhythmic agents vernakalant and amiodarone were introduced in the model by inhibiting ap

293 Genes down-regulated by amiodarone were involved in all stages of cell cycle con

294 Both vernakalant and amiodarone were safe and well tolerated in this study.

295 r (ICD) therapy and appeared to be harmed by amiodarone, whereas New York Heart Association functiona

296 ximal inhibition was observed with 50 microM amiodarone which inhibited 85.6 +/- 3.1% of IKAS induced

297 nd HepG2 cells uptake the greatest amount of amiodarone with an average of 2.38 and 2.60 pg per cell,

298 randomized trial, we compared ICD therapy or amiodarone with state-of-the-art medical therapy alone i

299 The majority of genes induced by amiodarone within 10 min were involved in utilization of

300 1 show growth sensitivity to multiple drugs (amiodarone, wortmannin, sulfometuron methyl, and tunicam